Recent evidence highlighted a pathogenetic link between redox dysregulation and the early stages of psychosis. Indeed, an increasing number of studies have pointed toward an association between oxidative stress, both at central and peripheral levels, and first psychotic episode. Moreover, basal low antioxidant capacity has been shown to directly correlate with cognitive impairment in the early onset of psychosis. In this context, the possibility to use antioxidant compounds in first psychotic episode, especially as supplementation to antipsychotic therapy, has become the focus of numerous investigations on rodents with the aim to translate data on the possible effects of antioxidant therapies to large populations of patients, with a diagnosis of the first psychotic episode. In this review, we will discuss studies, published from January 1st, 2007 to July 31st, 2017, investigating the effects of antioxidant compounds on neuropathological alterations observed in different rodent models characterized by a cluster of psychotic-like symptoms reminiscent of what observed in human first psychotic episode. A final focus on the effective possibility to directly translate data obtained on rodents to humans will be also provided.
| INTRODUC TI ON
The progression period from a healthy mental status to a psychotic state is characterized by a high vulnerability of the central nervous system (CNS) to several neurodetrimental stimuli, such as redox dysregulation and oxidative stress, 1 defined as a disequilibrium between production of reactive oxygen species (ROS) and antioxidant defense. 2 The most redox-sensitive cellular subpopulation in the CNS is represented by the fast-spiking parvalbumin interneurons, which are known to be highly affected during the complex pathological events leading to first psychotic episode. 3 Indeed, for the maintenance of their physiological state, they need large amount of energetic resources, together with well-functioning ROSgenerating and ROS-degrading systems. [4] [5] [6] Importantly, fast-spiking parvalbumin interneurons have been described as a highly oxidative stress-sensitive neuronal subtype, especially during the postnatal period and this also affects all the molecular pathways leading to their maturation. [7] [8] [9] Oligodendrocytes are also very vulnerable to redox dysregulation, in particular during the process of myelination which requires the activation of several metabolic pathways, 10, 11 resulting in an abundant ROS production accompanied by a decreased basal activity of specific antioxidant systems, such as glutathione. 12 An altered redox state has been also described as a major interference for oligodendrocyte maturation and development, 7, 13 because of a pathogenetic link existing between glutathione deficits in oligodendrocyte progenitors and a decreased proliferation of these cells. 14 Phospholipid and polyunsaturated fatty acids (PUFA), which are known to be crucial structural elements of CNS cell membranes, have been also described as particularly vulnerable to the increased production of free radicals as well as to the decrease in antioxidant defense. 15 Moreover, a significant association among negative symptoms occurring in first psychotic episode, oxidative stress, decreased PUFA content, and increased levels of lipid peroxidation has been reported. 16, 17 In this context, pharmacological compounds specifically targeting an imbalanced redox state may represent promising therapeutic opportunities to prevent oxidative stress-induced deleterious effects on cortical and hippocampal parvalbumin interneurons and oligodendrocytes. Intuitively, their benefits would be more evident if they could be administered in the very early phases of the disease, as first psychotic episodes could be clinically considered. 1 In this review, studies published from January 1st, 2007 to July 31st, 2017, focused on the effects of antioxidant compounds on neuropathological alterations observed in different rodent models presenting psychotic-like symptoms reminiscent of human first psychotic episode, will be discussed. A final comment on the real possibility to directly translate rodent data to patients will be also provided. We obtained a total of 300 publications, including 7 duplicative records which were removed from further screening. For the evaluation of the 293 remaining articles, the following inclusion criteria were considered: (i) publication language (only English language publications were included); (ii) type of publication (we only considered original research articles and reviews); (iii) subjects of the study (only studies on rodents were included); (iv) description of the used antioxidant compounds (only studies, in which administration of antioxidants has been clearly described, in terms of type of compounds and dosage, were considered). Using these criteria, we excluded 207 records and assessed for eligibility 86 full-text articles. We further screened them excluding works (26) which: (i) did not include control groups; (ii) did not clearly report the behavioral validation of the used animal model; resulting, finally, in a total of 60 studies considered for the qualitative synthesis. The PRISMA diagram related to our literature search methodology is reported in Figure 1 . The final list of the references for the writing of this review also enclosed publications cited in the Introduction paragraph and in the opening statements of the other sections of this manuscript.
| LITER ATURE S E ARCH ME THODOLOGY

| ANIMAL MODEL S OF FIR S T PSYCHOTI C EPISODE: AN E XIS TING TOOL?
An "animal model" is labeled as an "approximation of a specific human condition or disease". 18 
| EFFEC TS OF ANTI OXIDANT TRE ATMENTS
Emerging lines of evidence have described the effects of different antioxidant treatments in rodent models mimicking first psychotic episode. icking the first phases of the psychotic disease. 57 An antioxidant treatment with this glutathione precursor has showed significant positive effects in preventing or strongly ameliorating neuropathological and behavioral alterations observed in the ketamine perinatal model of psychosis, such as decreased cognitive abilities, reduced social interactions, dysfunctions in the ability to recognize a novel object with respect to a familiar one, and reduced prepulse inhibition. 58 In an elegant study of das Nueve Duarte and co-authors, performed using mice knock-out for the GSH-synthesizing enzyme glutamate-cysteine ligase modulatory subunit (GCLM-KO), which were characterized by chronic GSH deficit associated to specific cortical neurochemical changes especially at the prepubertal age, N-acetylcysteine, administered from gestation, has been shown to induce a normalization of all neuropathological alterations observed in GCLM-KO mice. 59 Using the same knock-out mice, Cabuncgal and co-authors demonstrated that a treatment with N-acetylcisteine prevented the detrimental effects of oxidative stress occurring in crucial moments of CNS postnatal development, such as the hampered maturation of parvalbumin-positive interneurons. 13 In the same line, another research group demonstrated, using G72/G30 transgenic mice which exhibit several early psychotic-like behavioral alterations, that N-acetylcysteine administration in the perinatal period was able to rescue neuropathological alterations observed in these rodents, such as the decreased activity of the mitochondrial complex I, associated to consequent increase in free radical production, impaired synaptic plasticity, deficits in learning processes, as well as spatial memory acquisition and consolidation. 60 In another preclinical study, N-acetylcysteine, administered to socially isolated rats during perinatal life and from the beginning of the isolation procedure, has been shown to reverse mitochondrial, immunological, neurochemical, and behavioral deficits induced by social isolation and this effect was more significant when N-acetylcysteine was coadministered with clozapine. 
| N-acetylcysteine
| Apocynin
Another ROS scavenger/antioxidant compound, whose effects have been investigated in different animal models reminiscent of first psychotic episode, is apocynin, also known as acetovanillone. This compound has been also demonstrated to have an inhibitory action against NADPH oxidase, significantly preventing superoxide generation in granulocytes and resulting, finally, in beneficial effects against inflammatory processes. 62 One of the first evidence on the possible effects of this compound in animal models of psychosis came from the group of Behrens. Indeed, using the ketamine model of this mental disorder, this research group demonstrated that ketamine-induced neuropathological alterations, in terms of loss of expression of parvalbumin and GAD67 in the subpopulation of the cortical fast-spiking inhibitory interneurons, were associated to increased superoxide production by the NADPH oxidase NOX2 enzyme and that a treatment with apocynin, decreasing the production of this free radical, prevented ketamine-induced dysfunctions. 63 However, although extremely inno- Reversal of PPI deficits (56) first psychotic-like symptoms may occur. Other lines of evidence highlight the effects of this ROS scavenger in the developmental life period. Indeed, it has been demonstrated that a chronic treatment with apocynin, started at 2 weeks of age, reduced the expression of specific markers of oxidative stress and partially solved behavioral psychotic-like symptoms in a NMDA-R hypofunction mouse model, also exposed to social isolation. 64 In the same line, we previously demonstrated that the antioxidant/NOX inhibitor apocynin, administered during the early phases of the psychotic state development induced by the procedure of the social isolation rearing, was able to fully reverse the observed behavioral alterations. Interestingly, if applied once the psychotic-like conditions have become chronic (at the adult age), this same compound could only partially reverse the neuropathological alterations induced by social isolation. 65 Furthermore, apocynin treatment in rats isolated during the developmental period and, therefore, presenting first psychotic-like neuropathological alterations, could also stop the progression of neuroendocrine alterations induced by social isolation. 42 Supporting these findings, apocynin treatment from PND 6 to PND 8 in ketamine-treated rat pups was able to attenuate the ketamine-induced alterations in memory and learning abilities, the increased expression of markers of oxidative stress, as well as of NOX2 enzyme, and the decreased expression of parvalbumin and GAD67 in cortical inhibitory interneurons. 
| Other antioxidant compounds
Based on our literature search strategy, preclinical studies describing the use and the effects of other antioxidant compounds than N-acetylcisteine and apocynin in rodent models of psychosis which mimics specifically first psychotic symptoms are quite limited and mainly referred to the following compounds: vitamin C, omega-3 fatty acids, and ebselen. Evidence about these three compounds is summarized in Table 1 .
| FUTURE D IREC TI ON S AND CON CLUS IONS
If it should always be taken into account that each existing animal model for any kind of disease has its own strengths and weaknesses, this concept appears to be even more significant for rodent models of psychosis, in particular for those who have been developed to mimic the neuropathological events and alterations in behavior occurring in human first psychotic episode. However, psychiatric research, performed using these animal models, has largely contributed to the identification of novel pharmacologi- 
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